Publication | Open Access
Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E.
32
Citations
0
References
1990
Year
Retroviral InfectionImmunologyMolecular BiologyImmunologic MechanismInnate ImmunityImmunotherapyInflammationHuman RetrovirusReceptor Tyrosine KinaseSynthetic PeptidePeptide ConjugateCell SignalingProtein Kinase CVirologyAutoimmunityCell BiologyCytokineSignal TransductionMolecular VirologyAntiviral ResponseEnvelope Protein P15eMedicineViral ImmunityRetroviral Protein P15e
Retroviral infection is associated with immunosuppression, which has been shown to be due, in part, to the action of the envelope protein p15E. We studied a synthetic peptide (CKS-17) homologous to a highly conserved domain of the retroviral envelope protein p15E, which, when conjugated to BSA (CKS-17-BSA), can inhibit IL-1- and phorbol ester-mediated responses in cultured murine thymoma cells, and Ca2(+)- and phosphatidylserine-dependent protein kinase C (PKC) activity of cell homogenates. We characterized the mechanism of inhibition of PKC by the peptide. Using PKC purified from rat brain we found that CKS-17-BSA inhibited PKC-catalyzed Ca2(+)- and phosphatidylserine-dependent histone phosphorylation with an estimated ID50 of 4 microM. CKS-17-BSA did not inhibit the catalytic subunit of cAMP-dependent protein kinase. CKS-17-BSA also inhibited the Ca2(+)- and PS-independent activity of a catalytic fragment of PKC that was generated by limited trypsin treatment. However, CKS-17-BSA did not act as a competitive inhibitor of PKC with respect to ATP or phosphoacceptor substrate, despite the similarity between the CKS-17 sequence and substrates and pseudosubstrates of PKC. We conclude that this peptide homologue of a retroviral envelope protein has a novel mechanism of inhibition of PKC.